The country of origin of Aceclidine Ophthalmic Solution (Aceclidine Hydrochloride 1.75%)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredient Aceclidine Hydrochloride (made in the United States) with the inactive ingredients into the final dosage Aceclidine Ophthalmic Solution in Germany does not result in a substantial transformation and the country of origin will be the United States.
Ruling text
In your letter dated October 17, 2024, you requested a country of origin ruling on Aceclidine Ophthalmic Solution. Aceclidine Ophthalmic Solution is a medicinal preparation containing Aceclidine Hydrochloride, a parasympathomimetic miotic agent, as the active ingredient. Currently it is under development for the treatment of presbyopia in adult patients, an age-related eye condition that makes it difficult to focus on nearby objects.
The Aceclidine Ophthalmic Solution will be packaged in single-use, blow-fill seal (BFS) ampoules (0.4 mL nominal fill volume) and shipped in cartons containing 5 pouches of 5 ampoules each (25 ampoules total). You stated that the active pharmaceutical ingredient (API), Aceclidine Hydrochloride, is manufactured in the United States and that the finished Aceclidine Ophthalmic Solution in dosage form is made in Germany.
In Germany, the Aceclidine Hydrochloride will be mixed with inactive ingredients to produce the final Aceclidine Ophthalmic Solution in dosage form. Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production, or growth of any article of foreign origin entering the United States.
Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; …. A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact.
See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986). In this case, we find the mixing of the active ingredient Aceclidine Hydrochloride (made in the United States) with the inactive ingredients into the final dosage Aceclidine Ophthalmic Solution in Germany does not result in a substantial transformation and the country of origin will be the United States.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1). This section states that a ruling letter is issued on the assumption that all of the information furnished in the ruling letter, whether directly, by reference, or by implication, is accurate and complete in every material respect.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N343405).